Progress in the medical field for QMC continues."t
Post# of 22453
Maybe
From August 25 2021 update
Next generation of diagnostic testing
Quote:
We are currently developing 1) LFTs (lateral flow test kits) for TBI (traumatic brain injury, aka concussions), 2) a multiplex test that detects Covid-19, Flu and RSV (Respiratory Syncytial Virus), and 3) a vaccine validator to thwart counterfeit vaccines and validate vaccine efficacy.
We believe the POCT market is poised for significant growth and the need for rapid, low-cost, highly sensitive, and quantitative point of care tests can best be meet with quantum dot enabled technologies. We intend to continue the expansion of our biotech staff and capabilities, provided we are able to generate sufficient cash flows from operations or through additional financing. This technology is intended to part of our immediate commercialization focus.
and
Combating Counterfeit Medicines
Quote:
Our scientific team has developed the quantum dot printing process necessary to print covert or overt quantum dot Q.R. codes, Bar Codes, serial numbers, or a wide range of other unique features. These can be excited by various energy sources and emit light across the spectrum. They have also developed the processes and quantum dot ink solutions necessary to print these features on multiple surfaces, including glass, film, paper, and even pearls. We still believe our quantum dot ink and blockchain-based anti-counterfeiting, track and trace platform has enormous potential and can become the de facto anti-counterfeiting solution for a broad range of applications. Recently, the Company successfully completed the first phase of a funded proof of concept of an authentication solution for one of the world's largest tobacco manufacturers. This solution is based on our food-grade IR emitting nano-materials. This product will be focused on to the extent that it can be supported by a strategic partner(s)
.
FDA: Drug Supply Chain Security Act (DSCSA),
https://www.fda.gov/drugs/buying-using-medici...t-medicine 02/03/2022
:
Quote:
FDA is implementing key provisions of the Drug Supply Chain Security Act (DSCSA), which outlines steps to achieve interoperable, electronic tracing of product at the package level to identify and trace certain prescription drugs as they are distributed in the U.S
Quote:.
FDA issued a draft guidance for industry on anti-counterfeiting for pharmaceutical manufacturers who want to use physical-chemical identifiers (PCIDs) in solid oral dosage forms (SODFs). A PCID is a substance or combination of substances possessing a unique physical or chemical property that unequivocally identifies and authenticates a drug product or dosage form
are possible markets?